The field expects to be close to a new era of groundbreaking therapies. With new biological insights, scientists and clinicians are on the verge of finding drugs for ALS that can slow or even stop degeneration in the neurons controlling our muscles. The development of disease-modifying ALS drugs is estimated to lead to a multi-billion dollar market in ALS. Some of these drugs could potentially work in other, more common, neurodegenerative diseases, further increasing the potential value of the companies developing these drugs. As a result, over the past few years we have seen a steep growth in ALS drug development efforts in the biotech sector, including the launch of a large number of privately held biotech companies, which are our investment targets. Large pharmaceutical corporations are also moving into this area and looking to acquire such companies.